Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Duvakitug in Moderately to Severely Active Ulcerative Colitis
NCT07184996Phase 3Recruiting
- Sponsor
- Sanofi
- Start
- Oct 2025
- Primary completion
- May 2028
- Modality
- Monoclonal Antibodies
- Countries
- 25
01
Overview
A Phase 3 trial of duvakitug in ulcerative colitis (UC), sponsored by Sanofi. Started Oct 2025; status: recruiting.
02
Drugs
duvakitug
03
Conditions
ulcerative colitis (UC)
Beyond the preview
Go deeper on NCT07184996.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07184996.